NZ528321A - Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders - Google Patents

Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders

Info

Publication number
NZ528321A
NZ528321A NZ528321A NZ52832102A NZ528321A NZ 528321 A NZ528321 A NZ 528321A NZ 528321 A NZ528321 A NZ 528321A NZ 52832102 A NZ52832102 A NZ 52832102A NZ 528321 A NZ528321 A NZ 528321A
Authority
NZ
New Zealand
Prior art keywords
amyloid
disease
amyloidosis
catechin
green tea
Prior art date
Application number
NZ528321A
Other languages
English (en)
Inventor
Gerardo M Castillo
Paula Y Choi
Joel A Cummings
Beth P Nguyen
Alan D Snow
Original Assignee
Proteotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteotech Inc filed Critical Proteotech Inc
Publication of NZ528321A publication Critical patent/NZ528321A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
NZ528321A 2001-03-15 2002-03-15 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders NZ528321A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27686601P 2001-03-15 2001-03-15
US33896901P 2001-12-10 2001-12-10
PCT/US2002/007755 WO2003013442A2 (en) 2001-03-15 2002-03-15 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders

Publications (1)

Publication Number Publication Date
NZ528321A true NZ528321A (en) 2006-09-29

Family

ID=26958170

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ528321A NZ528321A (en) 2001-03-15 2002-03-15 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders

Country Status (9)

Country Link
EP (1) EP1372682B1 (enExample)
JP (1) JP2004537576A (enExample)
AT (1) ATE555807T1 (enExample)
CA (1) CA2440293C (enExample)
DK (1) DK1372682T3 (enExample)
ES (1) ES2387910T3 (enExample)
NZ (1) NZ528321A (enExample)
PT (1) PT1372682E (enExample)
WO (1) WO2003013442A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP1663199B1 (en) * 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
EP1713457A2 (de) * 2004-02-11 2006-10-25 Max-Delbrück-Centrum Für Molekulare Medizin Neue arzneimittel und diagnostische zusammensetzungen f r be handlung und diagnose von neurodegenerativen erkrankungen und amyloid-krankheiten
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US20100040558A1 (en) * 2005-04-26 2010-02-18 University Of South Florida Green tea polyphenol alpha secretase enhancers and methods of use
JP2007022946A (ja) * 2005-07-14 2007-02-01 Mitsui Norin Co Ltd マクロファージ遊走阻止因子の酵素活性阻害剤
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
GB2463833B (en) * 2007-06-26 2012-02-08 Parkinson S Inst Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
JP5738755B2 (ja) * 2008-05-09 2015-06-24 アイカーン スクール オブ メディシン アット マウント シナイ 神経変性疾患を予防および治療するための方法
JP6068484B2 (ja) 2011-10-24 2017-01-25 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法
US20180271927A1 (en) * 2015-05-27 2018-09-27 Nippon Paper Industries Co., Ltd. Brain function-protecting agent
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물
JPWO2019054461A1 (ja) * 2017-09-15 2020-08-27 株式会社明治 神経機能の維持または回復用組成物
CN109799352B (zh) * 2019-01-29 2022-03-08 北京健坤禾润科技有限公司 化学发光试剂及其在免疫检测中应用
JP2025513275A (ja) * 2022-04-20 2025-04-24 サンテック メディカル，インコーポレイティド 中枢神経系疾患の治療方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275905B1 (it) * 1995-03-14 1997-10-24 Indena Spa Frazioni polifenoliche di te', loro uso e formulazioni che le contengono
JPH10245342A (ja) * 1997-03-03 1998-09-14 Mitsui Norin Kk β−アミロイド蛋白の神経細胞毒性低減剤
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
EP1246632A4 (en) * 1999-12-30 2004-08-18 Proteotech Inc CATECHINE AND GREEN TEA EXTRACT FOR TREATING AMYLOIDOSES IN GENERAL OR. AT ALZHEIMER

Also Published As

Publication number Publication date
WO2003013442A2 (en) 2003-02-20
JP2004537576A (ja) 2004-12-16
ATE555807T1 (de) 2012-05-15
EP1372682B1 (en) 2012-05-02
CA2440293C (en) 2012-01-24
DK1372682T3 (da) 2012-08-20
EP1372682A2 (en) 2004-01-02
WO2003013442A3 (en) 2003-05-30
EP1372682A4 (en) 2005-10-19
ES2387910T3 (es) 2012-10-03
CA2440293A1 (en) 2003-02-20
PT1372682E (pt) 2012-08-03

Similar Documents

Publication Publication Date Title
US20110098349A1 (en) Cathechins for the treatment of systemic aa amyloidosis
CA2440293C (en) Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
CA2289531C (en) Composition and methods for treating alzheimer's disease and other amyloidoses
US20020086067A1 (en) Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
Wang et al. α-Mangostin, a polyphenolic xanthone derivative from mangosteen, attenuates β-amyloid oligomers-induced neurotoxicity by inhibiting amyloid aggregation
US6264994B1 (en) Compositions for treating alzheimer's disease and other amyloidoses
WO2000030666A1 (en) Composition and methods for inhibiting the formation of brain amyloid deposits
WO2000057707A1 (en) Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
JP4380991B2 (ja) アミロイド及びαシニュクライン疾患の治療のためのプロアントシアニジン
US10350258B2 (en) Compositions and methods for the treatment of plaques and tangles in humans and animals
US20020150637A1 (en) Methods of treating Alzheimer's disease and other amyloidoses using Hypericum perforatum and derivatives thereof
AU2002252347B2 (en) Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
AU2002252347A1 (en) Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
US11491201B2 (en) Compositions and methods for the treatment of “plaques and tangles” in humans and animals
Wang et al. Yishen Huazhuo Decoction Regulates Microglial Polarization to Reduce Neuroinflammation at the Early Stage of Alzheimer's Disease Through TREM2

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150218

LAPS Patent lapsed